Among all patients, the 5-year cancer-related survival rate in the plasma PROK1-positive group was significantly lower than that in the negative group (80.8% [95% CI 84.2‐96.6] vs. 92.6% [95% CI 65.3‐89.9], HR 2.68 [95% CI 1.13‐6.33], P = 0.02, Fig. 4A). This evidence concerns the gene PROK1 and cancer.